The disclosure includes compounds of Formulae (1) wherein Q.sub.1, Q.sub.2, Q.sub.3, Q.sub.4, Q.sub.5, Q.sub.6, Q.sub.7, Q.sub.8, Q.sub.x, R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.6, R.sub.7, R.sub.9, R.sub.10, R.sub.11, R.sub.x, a, b, c, g, j, k, m, n, u, v, L, Z.sub.1, Z.sub.2, Z.sub.4, and Z.sub.5 are defined herein. Also disclosed is a method for treating a neoplastic disease and autoimmune disease with these compounds.

##STR00001##

The invention provides novel substituted 6-arylamino pyridone carboxamides represented by Formula I, or a pharmaceutically acceptable salt, solvate, poly-morph, ester, tautomer or prodrug thereof, and a composition comprising these compounds. The compounds provided can be used as inhibitors of MEK and are useful in the treatment of inflammatory diseases, cancer and other hyperproliferative diseases. The invention further provides a method of treatment for inflammatory diseases, cancer and other hyperproliferative diseases in mammals, especially humans. ##STR00001##

This invention relates to generally inhibiting histone deacetylase (HDAC) enzymes (e.g., HDAC1, HDAC2, and HDAC3).

The ring-fused heterocyclic compound or a pharmaceutically acceptable salt thereof according to the present invention has a T-type calcium channel regulatory effect, and is useful, for example, as a medicament for treating and/or preventing pruritus. The present invention provides a ring-fused heterocyclic compound represented by the following general formula (I) or a pharmaceutically acceptable salt thereof and the like which has a T-type calcium channel regulatory effect and is useful as a therapeutic and/or preventive agent for pruritus, and the like. ##STR00001##
[wherein, R.sup.1 represents optionally substituted lower alkyl and the like, R.sup.2 represents optionally substituted lower alkyl and the like, R.sup.3 represents the formula (II): ##STR00002##
(wherein, n represents 0 or 1, R.sup.3a represents a hydrogen atom and the like, R.sup.3b represents a hydrogen atom and the like, and R.sup.3c represents a hydrogen atom and the like) and the like, Q represents a hydrogen atom and the like, and W.sup.1 represents a nitrogen atom and the like, W.sup.2 represents a nitrogen atom and the like].

The present disclosure relates to novel compounds of formula I-1, and pharmaceutical compositions thereof, and methods for inhibiting the activity of FGFR enzymes with the compounds and compositions of the disclosure. The present disclosure further relates to, but is not limited to, methods for treating disorders associated with FGFR signaling with the compounds and compositions of the disclosure. ##STR00001##

The present disclosure relates to novel compounds of formula I-1, and pharmaceutical compositions thereof, and methods for inhibiting the activity of FGFR enzymes with the compounds and compositions of the disclosure. The present disclosure further relates to, but is not limited to, methods for treating disorders associated with FGFR signaling with the compounds and compositions of the disclosure. ##STR00001##

The present disclosure provides compounds of the formula:

##STR00001##

and their pharmaceutically acceptable salts, as well as pharmaceutical compositions comprising these compounds and their use in the treatment of type II diabetes mellitus and obesity.

The present disclosure provides compounds of the formula:

##STR00001##

and their pharmaceutically acceptable salts, as well as pharmaceutical compositions comprising these compounds and their use in the treatment of type II diabetes mellitus and obesity.